This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
TG Therapeutics, Inc.
Drug Names(s): LFB-R603, TG-1101, TG20, TGTX-1101, Utuxin
LFB-R603 is a chimeric anti-CD20 recombinant monoclonal antibody directed towards the CD20 antigen expressed on the surface of B cells. The specific glycosylation profile of LFB-R603 gives it powerful ADCC (antibody-dependent cell-mediated cytotoxicity) activity directed against the tumor cells carrying this antigen. This exceptional high cytotoxicity has been demonstrated in non-clinical studies performed in vitro and in vivo experimental models.
TG Therapeutics is developing TG-1101 in combination with TGR-1202 under its 1303 program, seen here.
TG and LFB Biotechnologies
In April 2011, TG Therapeutics, a subsidiary of Manhattan Pharmaceuticals, acquired from LFB Biotechnologies an option for exclusive worldwide rights (except France/Belgium) to develop and market ublituximab.
In January 2012, TG Therapeutics exercised the License Option and entered into a license agreement with GTC Biotherapeutics, LFB Biotechnologies, and LFB/GTC LLC. In connection with the license agreement, TG Therapeutics issued 7,368,000 shares of its common stock to LFB, and the Company agreed to contribute $15 million, less applicable fees and expenses associated with the financing, to TG Therapeutics to fund the development of Utuxin under the license agreement, in exchange for 7,500,000 shares of TG Therapeutics common stock.
TG and Manhattan
In April 2012, Manhattan Pharmaceuticals filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals to TG...See full deal structure in Biomedtracker
Partners: LFB Group Ildong Pharmaceutical Co., Ltd.
Additional information available to subscribers only: